Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
Paolo GisondiFrancesco BellinatoGiovanni TargherLuca IdolazziGiampiero GirolomoniPublished in: Annals of the rheumatic diseases (2021)
bDMARDs treatment may delay or reduce the risk of incident PsA in patients with moderate-to-severe chronic plaque psoriasis.